The purpose of this multi center, open label, randomized, study is to obtain information on the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with viral pneumonia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Patients will receive inhalations of 150 ppm for 40 min 4 times a day, up to 7 days (maximum 28 treatments)
Shaare Zedek Medical Center
Jerusalem, Israel
Hasharon Medical Center
Petah Tikva, Israel
Rabin Medical Center
Petah Tikva, Israel
incidence of Serious Adverse Events
Clinical safety will be assessed by incidence of Serious Adverse Events (SAEs)
Time frame: 30 days
fever resolution
Time to fever resolution
Time frame: Baseline to 30 days
ICU admission
Number of patients requiring admission to ICU
Time frame: Baseline to 30 days
Oxygen support
Time until patient no longer requires supportive oxygen
Time frame: Baseline to 30 days
Stable room air saturation
b.d. Stable room air saturation of 93% and above or returning to baseline saturation, whichever is lower
Time frame: Baseline to 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.